Results 121 to 130 of about 55,011 (304)

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Obesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian   +9 more
wiley   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Obesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy   +6 more
wiley   +1 more source

The Effects of Glucagon-Like Peptide-1 Receptor Agonists of Liraglutide on Bone Turnover Makers Among Type 2 Diabetes Mellitus Patients: A Meta-Analysis of Randomized Controlled Trials

, 2022
Jing-yi Kang, Shanshan Lei, Jintao Guan
openalex   +1 more source

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT‐1 Trial

Obesity, EarlyView.
ABSTRACT Objective This prespecified subpopulation analysis aimed to assess the efficacy and safety of once‐weekly tirzepatide versus placebo alongside lifestyle intervention in Japanese adults with obesity or overweight. Methods Data from 102 Japanese adults in the SURMOUNT‐1 trial with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight‐related comorbidity ...
Yasushi Ishigaki, Masamichi Yamada, Tomotaka Shingaki, Tomonori Oura, Iichiro Shimomura   +4 more
wiley   +1 more source

Review for "Cardiovascular Outcomes Trials with Glucagon‐like Peptide‐1 Receptor Agonists: A Comparison of Study Designs, Populations, and Results"

, 2020

openalex   +1 more source

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

The Laryngoscope, EarlyView.
Alina Zgardau, Ryan Chin Taw Cheong, Kenny Peter Pang, Brian W. Rotenberg   +3 more
wiley   +1 more source

The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation [PDF]

, 2012
Y. J. Park, Z. Ao, Timothy J. Kieffer, H. Chen, Nooshin Safikhan, David Thompson, Mark Meloche, Garth L. Warnock, Lucy Marzban   +8 more
openalex   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

Slow Transit Constipation: Pathophysiological Perspectives and Management Updates

Journal of Digestive Diseases, EarlyView.
Slow transit constipation (STC) is a complex neuromuscular disorder driven by interstitial cells of Cajal (ICCs) loss and enteric neuropathy. Diagnosis relies on objective transit testing while excluding pelvic floor dysfunction. Management follows a stepwise, phenotype‐driven approach, progressing from conventional laxatives to emerging targeted ...
Athanasios Syllaios, Stavros P. Papadakos, Alexandros Ioannou, Maximos Frountzas, Dimosthenis Michelakis, Dimitrios Patsouras, Spyridon Dritsas, Manousos‐Georgios Pramateftakis, Dimitrios Schizas   +8 more
wiley   +1 more source